U.S. Markets closed

BioLineRx Ltd. (BLRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5800-0.0600 (-3.66%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6400
Open1.6400
Bid1.5200 x 800
Ask1.6900 x 900
Day's Range1.5600 - 1.6400
52 Week Range1.0600 - 3.0400
Volume123,136
Avg. Volume358,420
Market Cap31.324M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-2.3250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Radius Completes Enrollment in Phase III Osteoporosis Study
    Zacks

    Radius Completes Enrollment in Phase III Osteoporosis Study

    Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

  • BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
    PR Newswire

    BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that a sufficient number of patients (~65% of the original planned sample size) have been enrolled in the ongoing GENESIS Phase 3 trial to allow for an interim efficacy analysis to take place in the second half of 2020. This ongoing registrational study is investigating motixafortide (BL-8040) for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in patients with multiple myeloma. If the primary endpoint is met at the time of the interim analysis, the Company plans to immediately announce the cessation of further recruitment, without the need to enroll the full planned sample size. In this case, top-line results are expected in the first half of 2021, in order to maintain study blinding for all study endpoints, including those related to engraftment, for a period of 100 days subsequent to transplantation. If the primary endpoint is not reached in the interim analysis, the Company expects recruitment will continue until the originally planned sample size is met.

  • PR Newswire

    BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a corporate update.